{"organizations": [], "uuid": "beca85e0811ef7aeb742f3d578cf34d84f11eed4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-european-commission-approves-amgen/brief-european-commission-approves-amgen-allergans-mvasi-idUSFWN1PD1CY", "country": "US", "domain_rank": 408, "title": "BRIEF-European Commission Approves Amgen, Allergan's Mvasi", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-18T23:07:00.000+02:00", "replies_count": 0, "uuid": "beca85e0811ef7aeb742f3d578cf34d84f11eed4"}, "author": "", "url": "https://www.reuters.com/article/brief-european-commission-approves-amgen/brief-european-commission-approves-amgen-allergans-mvasi-idUSFWN1PD1CY", "ord_in_thread": 0, "title": "BRIEF-European Commission Approves Amgen, Allergan's Mvasi", "locations": [], "entities": {"persons": [{"name": "allerga", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "allergan", "sentiment": "negative"}, {"name": "brief-european commission approves amgen", "sentiment": "negative"}, {"name": "amgen", "sentiment": "negative"}, {"name": "mvasi reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 18, 2018 / 9:08 PM / Updated 8 minutes ago BRIEF-European Commission Approves Amgen, Allergan's Mvasi Reuters Staff 1 Min Read \nJan 18 (Reuters) - Amgen Inc: \n* EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN‘S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER \n* AMGEN INC - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-18T23:07:00.000+02:00", "crawled": "2018-01-18T23:28:33.006+02:00", "highlightTitle": ""}